Investigational drug · Phase 3
Felzartamab
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
8 still active
All registered trials
16
Any phase or sponsor naming "Felzartamab"
First trial start
2024
Dec 3, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Felzartamab", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Antibody-mediated Rejection
- Microvascular Inflammation
- Graves' Disease
- Generalized Myasthenia Gravis
- Immunoglobulin A Nephropathy (IgAN)
- Immunoglobulin A Nephropathy
- Primary Membranous Nephropathy
Approved drugs for the same conditions: Myasthenia gravis · IgA nephropathy · Neurology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Felzartamab" as an intervention, largest first.
- A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)Pivotal-lookingRecruiting
BiogenBiogen (BIIB)
NCT06935357 · 454 participants (planned) · Start May 8, 2025 · Primary completion May 31, 2027
Drug: Felzartamab; Placebo · For: Immunoglobulin A Nephropathy (IgAN)
Sites: Little Rock, Arkansas; Apple Valley, California; Carlsbad, California · 265 sites in all
- A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)Pivotal-lookingEnrolling by invitation
BiogenBiogen (BIIB)
NCT07444489 · 201 participants (planned) · Start Apr 16, 2026 · Primary completion Dec 31, 2031
Drug: Felzartamab · For: Antibody-mediated Rejection; Microvascular Inflammation
Sites: Los Angeles, California; San Francisco, California; Rochester, Minnesota · 15 sites in all
- A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)Pivotal-lookingRecruiting
BiogenBiogen (BIIB)
NCT06962800 · 180 participants (planned) · Start May 22, 2025 · Primary completion Jan 28, 2030
Drug: Felzartamab; Tacrolimus and 1 more · For: Primary Membranous Nephropathy
Sites: Huntsville, Alabama; Fresno, California; Los Angeles, California · 117 sites in all
- A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)Pivotal-lookingActive, not recruiting
BiogenBiogen (BIIB)
NCT06685757 · 132 participants · Start Dec 3, 2024 · Primary completion Dec 1, 2026
Drug: Felzartamab; Placebo · For: Antibody-mediated Rejection
Sites: Los Angeles, California; Orange, California; San Bernardino, California · 56 sites in all
MorphoSys AGIndustry
NCT01421186 · 91 participants · Start Jul 2011 · Primary completion Aug 2020
Drug: MOR03087 phase 1 dose escalation; MOR03087 and 3 more · For: Multiple Myeloma
Sites: Vienna, Austria; Berlin, Germany; Dresden, Germany · 10 sites in all
BiogenBiogen (BIIB)
NCT07219043 · 81 participants (planned) · Start Jan 5, 2026 · Primary completion Feb 10, 2028
Drug: Felzartamab; Placebo · For: Microvascular Inflammation
Sites: Loma Linda, California; Los Angeles, California; Orange, California · 53 sites in all
BiogenBiogen (BIIB)
NCT07939802 · 75 participants (planned) · Start Nov 19, 2026 · Primary completion Sep 19, 2028
Drug: Felzartamab; Placebo · For: Generalized Myasthenia Gravis
BiogenBiogen (BIIB)
NCT07722546 · 60 participants (planned) · Start Jul 30, 2026 · Primary completion Jan 31, 2028
Drug: Felzartamab; Placebo · For: Graves' Disease
Sites: Glendale, Arizona; Los Angeles, California; San Jose, California · 15 sites in all
HI-Bio, A Biogen CompanyIndustry
NCT05065970 · 54 participants · Start Aug 31, 2021 · Primary completion Feb 6, 2023
Drug: Felzartamab · For: Immunoglobulin A (IgA) Nephropathy
Sites: Oxnard, California; Vacaville, California; Rochester, Minnesota · 59 sites in all
HI-Bio, A Biogen CompanyIndustry
NCT04145440 · 31 participants · Start Oct 15, 2019 · Primary completion Jan 19, 2022
Drug: MOR202 · For: Glomerulonephritis, Membranous; antiPLA2R Positive
Sites: Azusa, California; San Francisco, California; Torrance, California · 45 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Anti-CD38 therapy in kidney allograft antibody-mediated rejection and microvascular inflammation: a systematic review and evidence map.
Liang C, Wang C, Yin S, et al. · Transplant Rev (Orlando) 2026
- Anti-CD38 monoclonal antibodies in kidney disease: mechanistic rationale and emerging clinical evidence.
Kanbay M, Copur S, Gulmaliyev I, et al. · Nephrol Dial Transplant 2026
- Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial.
He H, Shang J, Wang Y, et al. · Lancet Haematol 2026
- Preservation of Humoral Immunity and Response to Vaccination in Patients With IgAN Treated With Felzartamab.
Barratt J, Shah M, Jones NS, et al. · Kidney Int Rep 2026
- Not all anti-CD38 antibodies are created equal: The epitope of felzartamab is partially DTT-resistant.
Zeretzke A, Trummer P, Habicht CP, et al. · Transfus Med 2026
- Prolonged CD38 targeting with felzartamab in antibody-mediated kidney transplant rejection: a biomarker-guided open-label phase 2 extension.
Mayer KA, Diebold M, Schrezenmeier EV, et al. · Lancet Reg Health Eur 2026
Also in development for Antibody-mediated Rejection
- ALXN2030Phase 21 trial
AstraZeneca · Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Biogen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.